Better Therapeutics Overview
Valuation check: MCAD's ROE is 317.73%, above the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow317.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for MCAD is 317.73%. That is above the sector sector average of -5.68%. Investors often review this figure alongside Better Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, MCAD currently prints 317.73% for ROE, while the sector average sits near -5.68%. That is roughly 5690.8% above the sector mean. Large gaps often invite a closer look at Better Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Better Therapeutics converts resources into returns. At 317.73%, MCAD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting MCAD's ROE (317.73%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
